open access

Vol 57, No 3 (2019)
Original paper
Submitted: 2019-09-04
Accepted: 2019-09-23
Published online: 2019-09-25
Get Citation

Diagnostic immunohistochemistry for canine cutaneous round cell tumours — retrospective analysis of 60 cases

Katarzyna Pazdzior-Czapula1, Mateusz Mikiewicz1, Michal Gesek1, Cezary Zwolinski1, Iwona Otrocka-Domagala1
·
Pubmed: 31553052
·
Folia Histochem Cytobiol 2019;57(3):146-154.
Affiliations
  1. Department of Pathological Anatomy, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego St. 13, 10-719 Olsztyn, Poland

open access

Vol 57, No 3 (2019)
ORIGINAL PAPERS
Submitted: 2019-09-04
Accepted: 2019-09-23
Published online: 2019-09-25

Abstract

Introduction. Canine cutaneous round cell tumours (CCRCTs) include various benign and malignant neoplastic processes. Due to their similar morphology, the diagnosis of CCRCTs based on histopathological examination alone can be challenging, often necessitating ancillary immunohistochemical (IHC) analysis. This study presents a retrospective analysis of CCRCTs.

Materials and methods. This study includes 60 cases of CCRCTs, including 55 solitary and 5 multiple tumours, evaluated immunohistochemically using a basic antibody panel (MHCII, CD18, Iba1, CD3, CD79a, CD20 and mast cell tryptase) and, when appropriate, extended antibody panel (vimentin, desmin, a-SMA, S-100, melan-A and pan-keratin). Additionally, histochemical stainings (May-Grünwald-Giemsa and methyl green pyronine) were performed.

Results. IHC analysis using a basic antibody panel revealed 27 cases of histiocytoma, one case of histiocytic sarcoma, 18 cases of cutaneous lymphoma of either T-cell (CD3+) or B-cell (CD79a+) origin, 5 cases of plas­macytoma, and 4 cases of mast cell tumours. The extended antibody panel revealed 2 cases of alveolar rhabdo­myosarcoma, 2 cases of amelanotic melanoma, and one case of glomus tumour.

Conclusions. Both canine cutaneous histiocytoma and cutaneous lymphoma should be considered at the beginning of differential diagnosis for CCRCTs. While most poorly differentiated CCRCTs can be diagnosed immunohis­tochemically using 1–4 basic antibodies, some require a broad antibody panel, including mesenchymal, epithelial, myogenic, and melanocytic markers. The expression of Iba1 is specific for canine cutaneous histiocytic tumours, and more sensitive than CD18. The utility of CD20 in the diagnosis of CCRCTs is limited.

 

Abstract

Introduction. Canine cutaneous round cell tumours (CCRCTs) include various benign and malignant neoplastic processes. Due to their similar morphology, the diagnosis of CCRCTs based on histopathological examination alone can be challenging, often necessitating ancillary immunohistochemical (IHC) analysis. This study presents a retrospective analysis of CCRCTs.

Materials and methods. This study includes 60 cases of CCRCTs, including 55 solitary and 5 multiple tumours, evaluated immunohistochemically using a basic antibody panel (MHCII, CD18, Iba1, CD3, CD79a, CD20 and mast cell tryptase) and, when appropriate, extended antibody panel (vimentin, desmin, a-SMA, S-100, melan-A and pan-keratin). Additionally, histochemical stainings (May-Grünwald-Giemsa and methyl green pyronine) were performed.

Results. IHC analysis using a basic antibody panel revealed 27 cases of histiocytoma, one case of histiocytic sarcoma, 18 cases of cutaneous lymphoma of either T-cell (CD3+) or B-cell (CD79a+) origin, 5 cases of plas­macytoma, and 4 cases of mast cell tumours. The extended antibody panel revealed 2 cases of alveolar rhabdo­myosarcoma, 2 cases of amelanotic melanoma, and one case of glomus tumour.

Conclusions. Both canine cutaneous histiocytoma and cutaneous lymphoma should be considered at the beginning of differential diagnosis for CCRCTs. While most poorly differentiated CCRCTs can be diagnosed immunohis­tochemically using 1–4 basic antibodies, some require a broad antibody panel, including mesenchymal, epithelial, myogenic, and melanocytic markers. The expression of Iba1 is specific for canine cutaneous histiocytic tumours, and more sensitive than CD18. The utility of CD20 in the diagnosis of CCRCTs is limited.

 

Get Citation

Keywords

canine cutaneous tumours; IHC diagnosis; histiocytoma; cutaneous lymphoma; plasmacytoma; mast cell tumour; alveolar rhabdomyosarcoma, amelanotic melanoma, glomus tumour

About this article
Title

Diagnostic immunohistochemistry for canine cutaneous round cell tumours — retrospective analysis of 60 cases

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 57, No 3 (2019)

Article type

Original paper

Pages

146-154

Published online

2019-09-25

Page views

3895

Article views/downloads

3568

DOI

10.5603/FHC.a2019.0016

Pubmed

31553052

Bibliographic record

Folia Histochem Cytobiol 2019;57(3):146-154.

Keywords

canine cutaneous tumours
IHC diagnosis
histiocytoma
cutaneous lymphoma
plasmacytoma
mast cell tumour
alveolar rhabdomyosarcoma
amelanotic melanoma
glomus tumour

Authors

Katarzyna Pazdzior-Czapula
Mateusz Mikiewicz
Michal Gesek
Cezary Zwolinski
Iwona Otrocka-Domagala

References (40)
  1. Fernandez NJ, West KH, Jackson ML, et al. Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors. Vet Pathol. 2005; 42(4): 437–445.
  2. Meuten DJ ed. Tumours in Domestic Animals, 5th ed. Ames: Wiley Blackwell; 2017.
  3. Sandusky GE, Carlton WW, Wightman KA. Diagnostic immunohistochemistry of canine round cell tumors. Vet Pathol. 1987; 24(6): 495–499.
  4. Cangul IT. Improved classification, diagnosis and prognosis of canine round cell tumours. Vet Sci Tomorrow. 2001; 4: 1–19.
  5. Erich SA, Constantino-Casas F, Dobson JM, et al. Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. In Vivo. 2018; 32(1): 7–17.
  6. Ramos-Vara JA, Kiupel M, Baszler T, et al. American Association of Veterinary Laboratory Diagnosticians Subcommittee on Standardization of Immunohistochemistry. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. J Vet Diagn Invest. 2008; 20(4): 393–413.
  7. Araújo M, Preis I, Lavalle G, et al. Histomorphological and immunohistochemical characterization of 172 cutaneous round cell tumours in dogs. Pesquisa Veterinária Brasileira. 2012; 32(8): 772–780.
  8. Paździor-Czapula K, Rotkiewicz T, Otrocka-Domagała I, et al. Morphology and immunophenotype of canine cutaneous histiocytic tumours with particular emphasis on diagnostic application. Vet Res Commun. 2015; 39(1): 7–17.
  9. Moore PF, Rossitto PV, Danilenko DM. Canine leukocyte integrins: characterization of a CD18 homologue. Tissue Antigens. 1990; 36(5): 211–220.
  10. Day MJ. Immunophenotypic characterization of cutaneous lymphoid neoplasia in the dog and cat. J Comp Pathol. 1995; 112(1): 79–96.
  11. Pierezan F, Mansell J, Ambrus A, et al. Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol. 2014; 151(4): 347–351.
  12. Fontaine J, Bovens C, Bettenay S, et al. Canine cutaneous epitheliotropic T-cell lymphoma: a review. Vet Comp Oncol. 2009; 7(1): 1–14.
  13. Mason DY, van Noesel CJ, Cordell JL, et al. The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. Eur J Immunol. 1992; 22(10): 2753–2756.
  14. SCHRENZEL M, NAYDAN D, MOORE P. Leukocyte differentiation antigens in canine cutaneous and oral plasmacytomas. Veterinary Dermatology. 1998; 9(1): 33–41.
  15. Ramos-Vara JA, Miller MA, Valli VEO. Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20. Vet Pathol. 2007; 44(6): 875–884.
  16. Jubala CM, Wojcieszyn JW, Valli VEO, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol. 2005; 42(4): 468–476.
  17. de Souza Junior DA, Santana AC, da Silva EZ, et al. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. Biomed Res Int. 2015; 2015: 142359.
  18. Walls AF, Jones DB, Williams JH, et al. Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol. 1990; 162(2): 119–126.
  19. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001; 25(7): 543–551.
  20. Gesek M, Rotkiewicz T, Otrocka-Domagała I, et al. Manifestation of Tumours in Domestic Animals in Warmia and Mazury (Poland) Between 2003 and 2011. Bulletin of the Veterinary Institute in Pulawy. 2014; 58(3): 439–446.
  21. Lee Gr, Ihrke PJ, Walder WJ, et al. Skin diseases of the dog and cat. Clinical and histopathologic diagnosis. 2th ed. Oxford: Blackwell Science Ltd. ; 2005.
  22. Moore PF. A review of histiocytic diseases of dogs and cats. Vet Pathol. 2014; 51(1): 167–184.
  23. Rakich PM, Latimer KS, Weiss R, et al. Mucocutaneous plasmacytomas in dogs: 75 cases (1980-1987). J Am Vet Med Assoc. 1989; 194(6): 803–810.
  24. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract. 2003; 33(3): 473–89, v.
  25. Moore PF, Olivry T. Cutaneous lymphomas in companion animals. Clin Dermatol. 1994; 12(4): 499–505.
  26. Oliveira FN, Elliott JW, Lewis BC, et al. Cutaneous mast cell tumor with epitheliotropism in 3 dogs. Vet Pathol. 2013; 50(2): 234–237.
  27. Smedley RC, Lamoureux J, Sledge DG, et al. Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. Vet Pathol. 2011; 48(1): 32–40.
  28. Ewing T, Pieper J, Stern A. Prevalence of CD20+ cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011-2018) in the USA. Veterinary Dermatology. 2018; 30(1): 51–e14.
  29. Moore PF, Olivry T, Naydan D. Canine cutaneous epitheliotropic lymphoma (mycosis fungoides) is a proliferative disorder of CD8+ T cells. Am J Pathol. 1994; 144(2): 421–429.
  30. Stilwell JM, Rissi DR. Immunohistochemical Labeling of Multiple Myeloma Oncogene 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Cutaneous Histiocytoma. Vet Pathol. 2018; 55(4): 517–520.
  31. Ribatti D. The Staining of Mast Cells: A Historical Overview. Int Arch Allergy Immunol. 2018; 176(1): 55–60.
  32. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984; 21(5): 469–474.
  33. Ozaki K, Yamagami T, Nomura K, et al. Mast cell tumors of the gastrointestinal tract in 39 dogs. Vet Pathol. 2002; 39(5): 557–564.
  34. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002; 39(6): 651–678.
  35. Ramos-Vara JA, Miller MA. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A. Vet Pathol. 2011; 48(2): 443–450.
  36. Otrocka-Domagala I, Pazdzior-Czapula K, Gesek M, et al. Aggressive, solid variant of alveolar rhabdomyosarcoma with cutaneous involvement in a juvenile labrador retriever. J Comp Pathol. 2015; 152(2-3): 177–181.
  37. Shinya K, Uchida K, Nomura K, et al. Glomus tumor in a dog. J Vet Med Sci. 1997; 59(10): 949–950.
  38. Dagli MLZ, Oloris SCS, Xavier JG, et al. Glomus tumour in the digit of a dog. J Comp Pathol. 2003; 128(2-3): 199–202.
  39. Furuya Y, Uchida K, Tateyama S. A case of glomus tumor in a dog. J Vet Med Sci. 2006; 68(12): 1339–1341.
  40. Park CH, Kozima D, Tsuzuki N, et al. Malignant glomus tumour in a German shepherd dog. Vet Dermatol. 2009; 20(2): 127–130.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl